Home›Research›Compare›Liraglutide vs Semaglutide
Peptide ComparisonLiraglutide vs Semaglutide
Both are Metabolic peptides.
Liraglutide
Victoza
Half-life: 13 hours
52 providers listed
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
806 providers listed
Semaglutide has a longer half-life than Liraglutide, so it generally needs less frequent dosing.
Liraglutide
Half-life
13 hours
Semaglutide
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Daily injection protocol preference | Liraglutide |
| Weekly injection protocol preference | Semaglutide |
| Longer post-approval safety record (FDA-approved 2010 vs 2017) | Liraglutide |
| Greater weight loss in head-to-head and phase 3 trials | Semaglutide |
| More provider options (52 vs 806) | Semaglutide |
| Oral formulation option (Rybelsus) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Liraglutide
Semaglutide
Liraglutide
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…
Semaglutide vs liraglutide for weight loss in adults with overweight or obesity
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
+4 more
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
About Liraglutide
GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Liraglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Liraglutide
Not enough vendor pricing yet.
Semaglutide
Where to source these peptides
Liraglutide
52 listed
Browse directory →
Providers offeringSemaglutide
806 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Liraglutide vs Semaglutide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/liraglutide/semaglutide